ArticleInfectious diseases of poverty2026
Signature of resistance gene evolution and pyrethroid resistance escalation in the major malaria vector Anopheles funestus across Kenyan malaria-endemic regions separated by the Rift Valley.
Article in Infectious diseases of poverty, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundLandscape features such as the Rift Valley (RV) can restrict gene flow in malaria vectors and influence resistance patterns. Here, we assessed Plasmodium infection rates, resistance alleles and profiles in Anopheles funestus s.s. populations across Kenyan malaria-endemic regions separated by the RV.
methodsAnopheles funestus s.s. populations in western, coastal and Kerio Valley (KV, within the RV) were genotyped for key resistance markers using polymerase chain reaction (PCR). TaqMan assay combined with nested PCR were used to screen the samples for Plasmodium sporozoite infection and association with resistance alleles and genotype frequencies assessed using Fisher's exact test or Pearson's chi-square test. Following established WHO guidelines, phenotypic resistance using F1 progeny was also assessed using diagnostic, intensity and piperonyl butoxide (PBO)-synergistic assays.
resultsThe 4.3kb-SV (n = 336) and G454A-Cyp9k1 (n = 445) alleles were nearly fixed in western Kenya but declined towards the RV and coast, whereas L119F-GSTe2 (n = 392) increased across a west-KV-coast gradient with a novel haplotype distinct from known African variants detected at the coast. There were lower odds of Plasmodium infection in mosquitoes with L119F-GSTe2-RR than RS genotype (OR 0.2, P = 0.046). Likewise, mosquitoes harboring the R allele of the 4.3 kb marker had higher Plasmodium infection rates than the S allele (OR 5.7, P = 0.049). An. funestus populations exhibited a high degree of pyrethroid resistance with intensity higher in KV compared to western Kenya, a traditional malaria hotspot. Pre-exposure to PBO increased mortality for type II (deltamethrin, alpha-cypermethrin), than I (permethrin) pyrethroids, yet mortality remained lower in KV, suggesting non-P450-mediated resistance. An. funestus mosquitoes from the coast showed extreme permethrin resistance (< 10% mortality at 10 × dose). Resistance to dichlorodiphenyltrichloroethane was widespread, while all populations remained fully susceptible to bendiocarb, pirimiphos-methyl, clothianidin, and chlorfenapyr.
conclusionsRegion-specific selection may drive varying resistance profiles in An. funestus across Kenyan malaria-endemic regions separated by the Rift Valley, with implications for malaria transmission and insecticide resistance management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.